Inovio Pharmaceuticals Inc (OQ:INO)
Business Focus: Biotechnology & Medical Research
Apr 15, 2024 06:39 pm ET
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PLYMOUTH MEETING, Pa., April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant, in each case before underwriting discounts and commissions. Gr
Mar 26, 2024 06:28 pm ET
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
PLYMOUTH MEETING, Pa., March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
Feb 21, 2024 07:00 am ET
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
PLYMOUTH MEETING, Pa., Feb. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter and year-end 2023 financial results will be released after the market close on March 6, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
Feb 07, 2024 10:46 am ET
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PLYMOUTH MEETING, Pa., Feb. 7, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
Feb 02, 2024 07:00 am ET
INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa., Feb. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
Jan 23, 2024 07:00 am ET
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
PLYMOUTH MEETING, Pa., Jan. 23, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Wednesday, January 24, 2024.
Jan 22, 2024 07:00 am ET
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
Fireside Chat, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, January 24, 2024, at 12:00pm ET
Jan 04, 2024 07:00 am ET
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
- Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer
Jan 03, 2024 07:00 am ET
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
Company will request Rolling Submission and Priority Review of its Biological License Application (BLA) by U.S. Food and Drug Administration (FDA) to expedite review processAccelerating commercialization efforts to be prepared to launch INO-3107 in 2025PLYMOUTH MEETING, Pa., Jan. 3, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced plans to submit a BLA for INO-3107 as a potential treatment for Recurrent Respirat
Nov 09, 2023 03:05 pm ET
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights
Achieved significant progress with lead product candidate, INO-3107 Received Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) as a potential treatment for Recurrent Respiratory Papillomatosis (RRP)Received FDA feedback that data from completed Phase 1/2 trial could be used to submit a Biological License Application (BLA) under Accelerated Approval programAccelerating commercialization strategy in preparation for an earlier launch, should regulatory approval be achievedIf approved, INO-3107 could revolutionize treatment options for patients with RRP, a debi
Nov 01, 2023 08:00 am ET
INOVIO Reports Inducement Grants Under Inducement Plan
PLYMOUTH MEETING, Pa., Nov. 1, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
Oct 26, 2023 08:00 am ET
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
PLYMOUTH MEETING, Pa., Oct. 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2023 financial results will be released after the market close on November 9, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
Oct 10, 2023 08:00 am ET
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission If approved, INO-3107 could potentially revolutionize treatment options for patients with Recurrent Respiratory Papillomatosis (RRP), a debilitating rare disease caused by human papillomavirus (HPV)INO-3107 could be the first DNA medicine available in the United States and the first commercial product for INOVIOPLYMOUTH MEETING, Pa., Oct. 10, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and pr
Sep 27, 2023 07:39 pm ET
Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million
-- Proceeds Will Fund Completion of GT-30 Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer --
Jul 26, 2023 09:32 am ET
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
PLYMOUTH MEETING, Pa., July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2023 financial results will be released after the market close on August 9, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
Jun 23, 2023 04:10 pm ET
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA: UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC....
Jun 01, 2023 08:00 am ET
INOVIO Reports Inducement Grants Under Inducement Plan
PLYMOUTH MEETING, Pa., June 1, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
May 25, 2023 08:00 am ET
INOVIO to Present at the 2023 Jefferies Healthcare Conference
PLYMOUTH MEETING, Pa., May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO, and Dr. Michael Sumner, CMO, will present at the 2023 Jefferies Healthcare Conference.
May 23, 2023 04:13 pm ET
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
PLYMOUTH MEETING, Pa., May 23, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Commission (EC) has granted orphan drug designation for INO-3107, the company's product candidate for the treatment of Recurrent Respiratory Papillomatosis (RRP). INO-3107 is an investigational DNA medicine candidate designed to elicit a targeted T cell response against HPV-6 and HPV-11, the HPV types that cause RRP
May 10, 2023 04:05 pm ET
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patientsSecond cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgical interventions in the year following initial treatmentNew combined safety and immunological data showing tolerability and durable immune response presented at ABEA/COSMAnnounced positive data from Phase 1b trial with INO-4201 as an Ebola booster for ERVEBO®INO-4201 was well-tolerated and boosted humoral responses in 36 of 36 (100%) treated participantsNew safety and immunological data indicati
May 08, 2023 08:00 am ET
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles)Data indicates INO-3107 was well tolerated and has the potential to provide clinical benefit to adults with RRPPLYMOUTH MEETING, Pa., May 8, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Re
May 05, 2023 08:00 am ET
INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
PLYMOUTH MEETING, Pa., May 5, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the 2023 RBC Capital Markets Global Healthcare Conference.
Apr 28, 2023 08:00 am ET
INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
PLYMOUTH MEETING, Pa., April 28, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2023 financial results will be released after the market close on May 10, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
Apr 27, 2023 08:00 am ET
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5th
Apr 26, 2023 08:00 am ET
European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107
European Commission to review and make a final decision, expected late May 2023
Apr 17, 2023 08:00 am ET
Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023
Oral presentation introduced new humoral and cellular response data indicating potential ability of INO-4201 to generate robust immune response and protect against Zaire ebolavirus
Apr 12, 2023 08:00 am ET
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023
Immunological data from recently completed Phase 1b trial will be presented on April 16th
Apr 03, 2023 08:00 am ET
INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa., April 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to its newly hired Senior Vice President, Regulatory Affairs under its 2022 Inducement Plan (the "Inducement Plan").
Feb 16, 2023 07:00 am ET
INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 patients did not need any surgeryTreatment with INO-3107 achieved statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous yearINO-3107 was well-tolerated and immunogenic, with efficacy and safety results for second cohort consistent with first cohortPatients in second cohort were administered INO-3107 using the exploratory side port needlePLYMOUTH MEETING, Pa., Feb. 16,
Feb 03, 2023 07:00 am ET
INOVIO Reports Inducement Grants Under Inducement Plan
PLYMOUTH MEETING, Pa., Feb. 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
Feb 02, 2023 07:00 am ET
INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
INO-4201 found to be well-tolerated in the trialHumoral responses were boosted in 100% (36 of 36) of treated participantsPLYMOUTH MEETING, Pa., Feb. 2, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo. In the trial, INO-420
Jan 31, 2023 07:00 am ET
INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates
Cost-saving measures include 11% headcount reductionAnnual savings expected to be approximately $4.3 millionData readouts expected in first quarter of 2023 for key programs including INO-3107 for RRP and VGX-3100 for cervical HSILPLYMOUTH MEETING, Pa., Jan. 31, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced a strategic reorganization that is intended to deliver on commitments to operational efficiency and be
Nov 17, 2022 03:30 pm ET
INOVIO Provides an Update on Lassa Fever and MERS Programs
PLYMOUTH MEETING, Pa., Nov. 17, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations (CEPI), to discontinue development of product candidates targeting Lassa Fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700), following initial analyses of data from studies conducted by INOVIO and funded by CEPI.
Nov 08, 2022 03:05 pm ET
INOVIO Reports Financial Results and Highlights for the Third Quarter 2022
Announced positive interim data for INO-3107 as a potential first-in-class treatment for Recurrent Respiratory PapillomatosisAdvanced strategy to focus on developing candidates that have the greatest opportunity for near-term successUpdates prior financial guidance and extends cash runway into first quarter of 2025Company will hold investor call today at 4:30 PM ETPLYMOUTH MEETING, Pa., Nov. 8, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associate
Oct 27, 2022 04:30 pm ET
INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800
PLYMOUTH MEETING, Pa., Oct. 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. The decision follows INOVIO's comprehensive review of its portfolio, market conditions, and global demand for COVID-19 vaccines.
Oct 25, 2022 08:00 am ET
INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022
PLYMOUTH MEETING, Pa., Oct. 25, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, announced today that third quarter 2022 financial results will be released after the market close on November 8, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
Oct 13, 2022 08:00 am ET
INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trialINO-3107 demonstrated statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous yearINO-3107 was found to be well-tolerated and immunogenicPLYMOUTH MEETING, Pa., Oct. 13, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and pr
Sep 01, 2022 08:00 am ET
INOVIO Reports Inducement Grants Under Inducement Plan
PLYMOUTH MEETING, Pa., Sept. 1, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from infectious diseases, cancer, and diseases associated with HPV, today announced that it has made equity grants to two newly hired employees, including a Vice President of Clinical Development, under its 2022 Inducement Plan (the "Inducement Plan").
Aug 30, 2022 08:00 am ET
INOVIO to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PLYMOUTH MEETING, Pa., Aug. 30, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference.
Aug 09, 2022 04:05 pm ET
INOVIO Reports Financial Results and Highlights for the Second Quarter 2022
Increased Cash Runway into Third Quarter 2024 with Cost-Savings and Corporate Restructuring Efforts Strengthened Executive Team with Appointment of Dr. Michael Sumner as Chief Medical Officer Announced Positive Data from a Phase 1/2 Trial with INO-5401 to treat Glioblastoma (GBM) at the American Society of Clinical Oncology (ASCO) Annual Meeting Will hold investor call today at 4:30 PM EDTPLYMOUTH MEETING, Pa., Aug. 9, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and
Jul 26, 2022 08:00 am ET
INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022
PLYMOUTH MEETING, Pa., July 26, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced today that second quarter 2022 financial results will be released after the market close on August 9, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. EDT to discuss financial results and provide a general business update.
Jul 19, 2022 08:00 am ET
INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients
Changes expected to reduce operational expenses and extend the company's cash runway into third quarter of 2024Improving cost structure will allow company to focus on strategic priorities, including heterologous boost strategy for COVID-19 vaccine candidate and HPV programsPLYMOUTH MEETING, Pa., July 19, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced that it has implemented a corporate reorganization de
Jun 27, 2022 08:00 am ET
INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO). Dr. Sumner will oversee INOVIO's clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs. He will serve on
May 27, 2022 08:00 am ET
INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022
INOVIO's DNA medicines immunotherapy in combination with Libtayo® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients
May 23, 2022 08:30 am ET
Thinking about buying stock in SIGA Technologies, Geovax Labs, Inovio Pharmaceuticals, ImmunoGen, or Emergent Biosolutions?
NEW YORK, May 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SIGA, GOVX, INO, IMGN, and EBS.
May 23, 2022 08:00 am ET
INOVIO to Present at Jefferies 2022 Healthcare Conference
PLYMOUTH MEETING, Pa., May 23, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, and Jeffrey Skolnik, M.D., SVP of Clinical Development for Oncology and HPV Therapeutics, are scheduled to participate in a fireside chat and 1x1 investor meetings at the Jefferies 2022 Healthcare Conference on Wednesday, June 8th, 2022 at 1:00 PM EDT.
May 19, 2022 10:55 am ET
Thinking about buying stock in Neurometrix, Grab, SIGA Technologies, Inovio Pharmaceuticals, or Roblox?
NEW YORK, May 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NURO, GRAB, SIGA, INO, and RBLX.
May 10, 2022 04:05 pm ET
INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer
Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech
May 10, 2022 04:05 pm ET
INOVIO Reports First Quarter 2022 Financial Results and Program Developments
Announces prioritization of heterologous booster strategy for COVID-19 vaccine candidate INO-4800 and discontinuation of Phase 3 INNOVATE trial to optimize potential impact on global public health Reports, with partner Advaccine, positive T cell immune response data with INO-4800 as a heterologous booster to an inactivated COVID-19 vaccine Announces change in plans for VGX-3100 following input from FDA on need for additional trials for a marketing application for the treatment of HPV-associated cervical high-grade squamous intraepithelial lesions Announces appointment of Jacqueline Shea, Ph.
Apr 26, 2022 08:00 am ET
INOVIO to Report First Quarter 2022 Financial Results on May 10, 2022
PLYMOUTH MEETING, Pa., April 26, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2022 financial results will be released after the market close on May 10, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
Mar 24, 2022 03:00 am ET
Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform
Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma
Mar 08, 2022 07:00 am ET
INOVIO to Present at Oppenheimer's 32nd Annual Healthcare Conference
PLYMOUTH MEETING, Pa., March 8, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will participate in a fireside chat and 1x1 investor meetings at Oppenheimer's 32nd Annual Healthcare Conference on Tuesday, March 15, 2021.
Mar 01, 2022 03:05 pm ET
INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results
PLYMOUTH MEETING, Pa., March 1, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today reported financial results for the quarter and year ended December 31, 2021. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir
Feb 15, 2022 07:00 am ET
INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022
PLYMOUTH MEETING, Pa., Feb. 15, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that fourth quarter 2021 financial results will be released after the market close on March 1, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
Dec 14, 2021 07:00 am ET
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
PLYMOUTH MEETING, Pa., Dec. 14, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL), including a one-year follow-up of efficacy and safety data in participants from REVEAL1, completing enrollment in REVEAL2, and advancing its pre-treatment biomarker candidate for VGX-3100 to be further
Nov 30, 2021 07:00 am ET
INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
PLYMOUTH MEETING, Pa., Nov. 30, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced the company is rapidly moving to evaluate its COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging B.1.1.529 (Omicron) variant of concern. Concurrently, INOVIO has initiated pre-clinical development of an Omicron-specific DNA vaccine candidate and will progress if needed.
Nov 29, 2021 07:30 am ET
Thinking about buying stock in Adagio Therapeutics, 180 Life Sciences, InMed Pharmaceuticals, Beyondspring, or Inovio Pharmaceuticals?
NEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, ATNF, INM, BYSI, and INO.
Nov 16, 2021 07:00 am ET
INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201
PLYMOUTH MEETING, Pa., Nov. 16, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase 1b clinical trial (NCT04906629). The trial will assess whether INO-4201 can be used as a booster in healthy volunteers previously vaccinated with rVSV-ZEBOV (Ervebo®1), an
Nov 15, 2021 07:00 am ET
INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference
PLYMOUTH MEETING, Pa., Nov. 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, announced today that eight company-sponsored presentations will be given this week at the 34th International Papillomavirus Conference (IPVC) , which is being held virtually from today, November 15 through Friday, November 19.
Nov 09, 2021 03:05 pm ET
INOVIO Reports Third Quarter 2021 Financial Results
PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat people with cancer, and HPV-associated diseases, today reported financial results for the quarter ended September 30, 2021. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at http://
Nov 09, 2021 07:00 am ET
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) provided authorization to proceed for INOVIO's INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S. The FDA has lifted the partial clinical hold following the FDA's review of additional non-clinical, clinical, and device information provided by INOV
Nov 05, 2021 08:00 am ET
INOVIO Expands Executive Leadership to Prepare for Commercial Operations
PLYMOUTH MEETING, Pa., Nov. 5, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the strategic appointments of new leaders designed to position INOVIO for growth and upcoming commercial operations. Effective immediately, four experienced and talented leaders will all join the executive team and report to INOVIO's President and CEO, Dr. J. Joseph Kim.
Nov 03, 2021 08:00 am ET
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
PLYMOUTH MEETING, Pa., Nov. 3, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, today announced that it has received authorization from India's Central Drugs Standard Control Organization (CDSCO)'s Drug Controller General of India (DCGI) to proceed with the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), in India for INO-4800, its DNA vaccine candidate for
Oct 27, 2021 08:00 am ET
INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021
PLYMOUTH MEETING, Pa., Oct. 27, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that third quarter 2021 financial results will be released after the market close on November 9, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's global Phase 3 efficacy trial (INNOVATE) involving its COVID-19 vaccine candidate, INO-4800.
Oct 26, 2021 08:00 am ET
INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa
PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced its Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, completed full enrollment of 220 participants. This trial (LSV-002 - NCT04093076) is ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, and is the first vaccine clinical trial for Lassa fever conducted in West Afric
Oct 21, 2021 08:00 am ET
INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives
PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the signing of a non-binding memorandum of understanding (MOU) with Colombia's Ministry of Health and Social Protection reflecting the intent to advance efforts to combat the pandemic and endemic threat posed by COVID-19 and to better prepare for future public health emergencies. The MOU creates a framework for a collaboration
Oct 12, 2021 08:00 am ET
INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800
PLYMOUTH MEETING, Pa., Oct. 12, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the online preprint publication in MedRxiv of Phase 1 clinical data on homologous boosting of its COVID-19 DNA vaccine candidate, INO-4800.
Oct 11, 2021 08:00 am ET
INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
PLYMOUTH MEETING, Pa., Oct. 11, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received authorization from Colombia's INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos, or the National Food and Drug Surveillance Institute), to conduct the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy) in Colombia, for INO-4800, its DN
Sep 29, 2021 08:00 am ET
INOVIO to Present Three Posters at IDWeek 2021
PLYMOUTH MEETING, Pa., Sept. 29, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, will present three posters at IDWeek 2021, taking place virtually from September 29th - October 3rd.
Sep 22, 2021 08:00 am ET
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
PLYMOUTH MEETING, Pa., Sept. 22, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received authorization from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), the national health regulatory agency of Mexico, to conduct a clinical trial in that country as part of the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy),
Sep 01, 2021 08:00 am ET
INOVIO to Present at Upcoming Investor Conferences in September
PLYMOUTH MEETING, Pa., Sept. 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor conferences in September:
Aug 26, 2021 08:00 am ET
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
PLYMOUTH MEETING, Pa., Aug. 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received regulatory authorization from Brazil's ANVISA (Agência Nacional de Vigilância Sanitária), the national health regulatory agency of Brazil, to initiate the global Phase 3 segment of its Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), for INO-4800, its DNA vaccine candidate for COVID-19
Aug 09, 2021 04:05 pm ET
INOVIO Reports Second Quarter 2021 Financial Results
PLYMOUTH MEETING, Pa., Aug. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended June 30, 2021. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update. The business update includes INOVIO's COVID-19 vaccine development efforts that address both current and
Aug 09, 2021 10:55 am ET
Thinking about buying stock in Inovio Pharmaceuticals, Sphere 3D, SOS Ltd, Zynga, or Future Fintech?
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INO, ANY, SOS, ZNGA, and FTFT.
Aug 09, 2021 08:00 am ET
INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate
PLYMOUTH MEETING, Pa. and SUZHOU, China, Aug. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received regulatory allowance for two clinical trials investigating heterologous boosting with INO-4800, its DNA vaccine candidate for COVID-19, through partner and trial-sponsor Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine") together with Sinovac Biotechnology ("Sinovac"). The studies w
Aug 04, 2021 08:00 am ET
INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease
PLYMOUTH MEETING, Pa., Aug. 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that the company has dosed the first Phase 2 trial subject in its quest to develop the first vaccine against the Middle East Respiratory Syndrome (MERS). INOVIO's Phase 2 trial is designed to evaluate INO-4700, its DNA vaccine candidate for the prevention of MERS, a disease in the coronavirus family for which there are no approved vaccines
Jul 26, 2021 08:00 am ET
INOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021
PLYMOUTH MEETING, Pa., July 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2021 financial results will be released after the market close on August 9, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's ongoing vaccine developments for COVID-19.
Jun 10, 2021 09:31 am ET
Thinking about buying stock in Sellas Life Sciences, ContextLogic, Corsair Gaming, Inovio Pharmaceuticals, or The GEO Group?
NEW YORK, June 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SLS, WISH, CRSR, INO, and GEO.
Jun 08, 2021 08:00 am ET
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
PLYMOUTH MEETING, Pa., June 8, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced an expansion of its previously announced partnership with Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine") to jointly conduct a global Phase 3 segment of the ongoing Phase 2/3 trial called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy). Together, the companies will evaluate the safety and efficacy of INO-4800 in
Apr 16, 2021 02:33 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of Inovio Pharmaceuticals, Inc. (NasdaqGS: INO), Merit Medical Systems, Inc. (NasdaqGS: MMSI), RCI Hospitality Holdings, Inc. (NasdaqGM: RICK), and Van
Inovio Pharmaceuticals, Inc. (NasdaqGS: INO) Lifshitz Law Firm, P.C. announces that on February 16, 2021, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss a putative class action complaint alleging that...
Apr 09, 2021 10:50 pm ET
INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO).
Feb 26, 2021 10:50 pm ET
INOVIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inovio Pharmaceuticals Inc. - INO
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO).
Feb 24, 2021 01:45 am ET
QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO’s VGX-3100 for Advanced Cervical Dysplasia
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO’s therapies.
(*Complementary when referring to the US regulatory pathway.)
Feb 24, 2021 12:45 am ET
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. (*Complementary when referring to the US regulatory pathway.)
Feb 23, 2021 07:00 am ET
INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa
PLYMOUTH MEETING, Pa., Feb. 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa fever to be conducted in West Africa, where the infection is en
Feb 16, 2021 07:00 am ET
INOVIO to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021
PLYMOUTH MEETING, Pa., Feb. 16, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that fourth quarter and year-end 2020 financial results will be released after the market close on March 1, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's ongoing vaccine developments for COVID-19.
Feb 12, 2021 07:30 am ET
Thinking about buying stock in Artelo Biosciences, Xeris Pharmaceuticals, Inovio Pharmaceuticals, Novan, or Fisker?
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARTL, XERS, INO, NOVN, and FSR.
Feb 05, 2021 08:31 am ET
Thinking about trading options or stock in Moderna, Johnson & Johnson, Pinterest, Ford, or Inovio Pharmaceuticals?
NEW YORK, Feb. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, JNJ, PINS, F, and INO.
Feb 03, 2021 10:00 am ET
Should you invest in Vaxart, Inovio Pharmaceuticals, Virgin Galactic, Blink Charging, or Jazz Pharmaceuticals?
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VXRT, INO, SPCE, BLNK, and JAZZ.
Feb 02, 2021 07:30 am ET
Thinking about buying stock in Artelo Biosciences, Vaxart, Inovio Pharmaceuticals, Vyne Therapeutics, or BioCryst Pharmaceuticals?
NEW YORK, Feb. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARTL, VXRT, INO, VYNE, and BCRX.
Feb 01, 2021 10:10 am ET
Should you invest in Inovio Pharmaceuticals, GameStop, Pan American Silver, Tesla, or General Electric?
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INO, GME, PAAS, TSLA, and GE.
Jan 29, 2021 10:15 am ET
Should you invest in Dillard's, Inovio Pharmaceuticals, Eli Lilly, Nektar Therapeutics, or Carnival Corp?
NEW YORK, Jan. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DDS, INO, LLY, NKTR, and CCL.
Jan 28, 2021 08:31 am ET
Thinking about buying stock in First Majestic Silver, Delta Air Lines, Norwegian Cruise Line, Inovio Pharmaceuticals, or SRAX Inc?
NEW YORK, Jan. 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AG, DAL, NCLH, INO, and SRAX.
Jan 25, 2021 03:01 pm ET
INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PLYMOUTH MEETING, Pa., Jan. 25, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the closing of its previously announced underwritten public offering of 20,355,000 shares of its common stock, which includes 2,655,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $8.50 per share. T
Jan 20, 2021 09:09 pm ET
INOVIO Announces Pricing of Public Offering of Common Stock
PLYMOUTH MEETING, Pa., Jan. 20, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50 per share. In addition, INOVIO has granted the underwriters a 30-day option to purchase up to an additional 2,655,000 shares of common stock at the public offering
Jan 20, 2021 03:30 pm ET
INOVIO Announces Proposed Public Offering of Common Stock
PLYMOUTH MEETING, Pa., Jan. 20, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. All of the shares are being offered by INOVIO. In addition, INOVIO intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares of
Jan 06, 2021 07:00 am ET
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18
PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced positive efficacy results for an open-label Phase 2 trial of VGX-3100 to treat HPV-16 and HPV-18-associated vulvar dysplasia. A 25% or more reduction in HPV-16/18-associated vulvar HSIL (high-grade squamous intraepithelial lesion) was observed for 63% of trial participants (12 of 19) treated with VGX-3100 at six months post-treatm
Jan 04, 2021 07:00 am ET
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine"), an emerging biotech company with next-generation technology in vaccines, both preventive and therapeutic, today announced that they have entered into a collaboration and license agreement for COVID-19 DNA vaccine candidate INO-4800.
Dec 24, 2020 08:31 am ET
Thinking about buying stock in Gevo Inc, Inovio Pharmaceuticals, Odonate Therapeutics, Cocrystal Pharma, or Vuzix Corp?
NEW YORK, Dec. 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEVO, INO, ODT, COCP, and VUZI.
Dec 24, 2020 08:14 am ET
INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine
PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants for its COVID-19 DNA vaccine candidate, INO-4800, in EClinicalMedicine, an open access clinical journal published by The Lancet.
Dec 15, 2020 08:31 am ET
Thinking about buying stock in Tcr2 Therapeutics, Inovio Pharmaceuticals, BioLineRx, Plug Power, or Arbutus Biopharma?
NEW YORK, Dec. 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TCRR, INO, BLRX, PLUG, and ABUS.
Dec 15, 2020 07:00 am ET
INOVIO to Develop DNA-encoded Monoclonal Antibody (dMAb®) Candidates to Treat COVID-19 with Funding from the Defense Advanced Research Projects Agency (DARPA) and the Department of Defense's (DoD) Joi
PLYMOUTH MEETING, Pa., Dec. 15, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the company and a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), a research and development agency of the U.S. Department of Defense (DoD) and the Joint Program Executive Office for Chemical, B
Dec 10, 2020 07:00 am ET
INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
PLYMOUTH MEETING, Pa. and SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine"), an emerging biotech company with next-generation technology in vaccines – both preventive and therapeutic, today announced the successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China. The Phase 2 clinical trial being con
Dec 09, 2020 07:00 am ET
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18
PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive Phase 2 efficacy results demonstrating that DNA medicine VGX-3100, the company's lead immunotherapy asset, showed resolution of HPV-16/18-associated precancerous anal lesions (HSIL) in 50% (11 of 22) of subjects six months following the start of treatment. The open label, single arm trial also showed VGX-3100 to be s
Dec 07, 2020 07:00 am ET
INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19
PLYMOUTH MEETING, Pa., Dec. 7, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject in a Phase 2 clinical trial evaluating DNA medicine INO-4800, its COVID-19 vaccine candidate, as part of its Phase 2/3 clinical trial, called INNOVATE (INovio INO-4800 Vaccine Trial for Efficacy). The Phase 2 segment of the trial will enroll approximately 400 participants who are 18 years or older at up to 17 U.S. sites to
Dec 04, 2020 07:30 am ET
Thinking about buying stock in Sutro Biopharma, BioCryst Pharmaceuticals, Inovio Pharmaceuticals, Cocrystal Pharma, or Clean Energy Fuels?
NEW YORK, Dec. 4, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STRO, BCRX, INO, COCP, and CLNE.
Dec 03, 2020 07:00 am ET
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.
PLYMOUTH MEETING, Pa., Dec. 3, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the execution of an agreement with Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation, for Eurogentec to manufacture INOVIO's COVID-19 vaccine candidate INO-4800 at their industry-leading GMP plasmid production scales. Terms of the agreement were not disclosed.
Nov 30, 2020 09:45 am ET
Thinking about buying stock in AMC Entertainment, Inovio Pharmaceuticals, Sundial Growers, Nikola Corp, or Sorrento Therapeutics?
NEW YORK, Nov. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, INO, SNDL, NKLA, and SRNE.
Nov 23, 2020 07:00 am ET
INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pa., Nov. 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject with DNA medicine INO-3107 in a Phase 1/2 clinical trial for the treatment of Recurrent Respiratory Papillomatosis (RRP).
Nov 20, 2020 08:31 am ET
Thinking about trading options or stock in Pfizer, Inovio Pharmaceuticals, Alibaba, General Electric, or Nio?
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, INO, BABA, GE, and NIO.
Nov 20, 2020 07:00 am ET
INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at
PLYMOUTH MEETING, Pa., Nov. 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced today that data from the company's novel combination trial of DNA medicines INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo® (cemiplimab) in the treatment of newly diagnosed glioblastoma (GBM), will be presented by Dr. David Reardon in the plenary session at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting. The study demonstra
Nov 16, 2020 07:30 am ET
Thinking about buying stock in Pfizer, Moderna, Inovio Pharmaceuticals, AMC Entertainment, or HighPoint Resources?
NEW YORK, Nov. 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, INO, AMC, and HPR.
Nov 16, 2020 06:00 am ET
INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense
PLYMOUTH MEETING, Pa., Nov. 16, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800, its COVID-19 vaccine candidate. The planned Phase 2/3 clinical trial, called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), is a randomized, blinded, placebo-controlled safety
Nov 09, 2020 03:05 pm ET
INOVIO Reports Third Quarter 2020 Financial Results
PLYMOUTH MEETING, Pa., Nov. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended September 30, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss financial results and provide a general business update, including near-term expectations for its COVID-19 DNA vaccine development program and a clinical program update for
Oct 26, 2020 08:00 am ET
INOVIO to Report Third Quarter 2020 Financial Results on November 9, 2020
PLYMOUTH MEETING, Pa., Oct. 26, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that third quarter 2020 financial results will be released after the market close on November 9, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's ongoing vaccine developments for COVID-19.
Jul 30, 2020 08:00 am ET
INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus
PLYMOUTH MEETING, Pa., July 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that its COVID-19 DNA vaccine INO-4800 targeting SARS-CoV-2 was effective in protecting non-human primates (NHPs; specifically rhesus macaques) from live virus challenge 13 weeks after the last vaccination. These protective results were mediated by memory T and B cell immune responses from INO-4800 vaccination.
Jul 29, 2020 09:31 am ET
Thinking about trading options or stock in Advanced Micro Devices, Starbucks, Inovio Pharmaceuticals, Boeing, or Caesars Entertainment?
NEW YORK, July 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, SBUX, INO, BA, and CZR.
Jul 29, 2020 07:30 am ET
INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pa., July 29, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis (RRP).
Jul 27, 2020 08:00 am ET
INOVIO to Report Second Quarter 2020 Financial Results on August 10, 2020
PLYMOUTH MEETING, Pa., July 27, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2020 financial results will be released after the market close on August 10, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update, including the company's ongoing vaccine developments for COVID-19.
Jul 14, 2020 09:31 am ET
Thinking about buying stock in Boxlight Corp, Novavax, Inovio Pharmaceuticals, Spirit Airlines, or Heat Biologics?
NEW YORK, July 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BOXL, NVAX, INO, SAVE, and HTBX.
Jul 07, 2020 09:31 am ET
Thinking about buying stock in Plug Power, Vaxart Inc, Inovio Pharmaceuticals, Aurora Cannabis, or Southwest Airlines?
NEW YORK, July 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLUG, VXRT, INO, ACB, and LUV.
Jul 01, 2020 09:31 am ET
Thinking about trading options or stock in FedEx Corp, Inovio Pharmaceuticals, Ford Motor, Boeing, or Plug Power?
NEW YORK, July 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FDX, INO, F, BA, and PLUG.
Jun 30, 2020 07:30 am ET
INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19
PLYMOUTH MEETING, Pa., June 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases and cancer, today announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts. In addition, INO-4800 has been selected to participate in a non-human primate (NHP) challenge study as part of the U.S. government's Operation Warp Speed, a new national program aiming to pro
Jun 29, 2020 09:31 am ET
Thinking about trading options or stock in Aptose Biosciences, Novavax, Inovio Pharmaceuticals, Ford Motor, or Carnival Corp?
NEW YORK, June 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APTO, NVAX, INO, F, and CCL.
Jun 26, 2020 09:31 am ET
Thinking about trading options or stock in Norwegian Cruise Line, Inovio Pharmaceuticals, VBI Vaccines, Sonos Inc, or Boeing?
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NCLH, INO, VBIV, SONO, and BA.
Jun 25, 2020 09:31 am ET
Thinking about buying stock in Sorrento Therapeutics, Rite Aid Corp, Inovio Pharmaceuticals, Seanergy Maritime Holdings, or United Airlines?
NEW YORK, June 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, RAD, INO, SHIP, and UAL.
Jun 25, 2020 08:00 am ET
INOVIO Expands Senior Management Team
PLYMOUTH MEETING, Pa., June 25, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has appointed two experienced senior executives to lead its growth in the Asia market and to advance the clinical development of its DNA vaccine INO-4800 to combat the COVID-19 pandemic.
Jun 24, 2020 09:31 am ET
Thinking about buying stock in Jiayin Group, Electrameccanica Vehicles, Inovio Pharmaceuticals, Novavax, or Hertz?
NEW YORK, June 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JFIN, SOLO, INO, NVAX, and HTZ.
Jun 23, 2020 09:31 am ET
Thinking about buying stock in Inovio Pharmaceuticals, Seelos Therapeutics, United Airlines, Thorney Opportunities, or Spirit Airlines?
NEW YORK, June 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INO, SEEL, UAL, TOP, and SAVE.
Jun 23, 2020 07:30 am ET
INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine
PLYMOUTH MEETING, Pa., June 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has received $71 million funding from the U.S. Department of Defense (DoD) to support the large-scale manufacture of the company's proprietary CELLECTRA® 3PSP smart device and the procurement of CELLECTRA® 2000 devices, which are used to deliver INO-4800 directly into the skin.
Jun 22, 2020 09:31 am ET
Thinking about trading options or stock in Nio Inc, Inovio Pharmaceuticals, Trade Desk Inc, American Airlines, or AT&T?
NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, INO, TTD, AAL, and T.
Jun 11, 2020 09:31 am ET
Thinking about trading options or stock in United Airlines, Plug Power, Carnival Corp, Advanced Micro Devices, or Inovio Pharmaceuticals?
NEW YORK, June 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UAL, PLUG, CCL, AMD, and INO.
Jun 04, 2020 06:00 am ET
INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea
SEOUL, South Korea and PLYMOUTH MEETING, Pa., June 4, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to start a Phase 1/2 clinical trial of INOVIO's COVID-19 vaccine INO-4800 in South Korea at a signing ceremony today. In attendance at the ceremony at SNU Hospital were IVI's Director General Dr. Jerome Kim and Deputy Director General of Science Dr. Manki Song, Dr. Anh Wartel (Associate Director General of EPIC and Head of Clinical Development and Regulatory) and Dr. Daniel Chul Woo Rhee (Pro
May 27, 2020 09:31 am ET
Thinking about trading stocks or options in Inovio Pharmaceuticals, Canopy Growth Corp, United Airlines, Rockwell Automation, or Wells Fargo?
NEW YORK, May 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INO, CGC, UAL, ROK, and WFC.
May 26, 2020 05:38 pm ET
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Inovio Pharmaceuticals, Inc. (INO)
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, develo
May 26, 2020 08:00 am ET
INOVIO to Host Webinar "DNA Medicines: From COVID-19 to Cancer"
PLYMOUTH MEETING, Pa., May 26, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases, cancer, and diseases associated with HPV, today announced it will hold a webinar event on June 1 from 10 AM to noon EDT to detail its proprietary DNA medicines technology and provide updates on INO-4800, its DNA vaccine in Phase 1 clinical development for COVID-19, and INO-5401, its DNA immunotherapy designed to treat glioblastoma multiforme (GBM), the most common a
May 20, 2020 09:31 am ET
Thinking about buying stock in Surface Oncology, Inovio Pharmaceuticals, American Airlines, Altimmune, or Aurora Cannabis?
NEW YORK, May 20, 2020 InvestorsObserver issues critical PriceWatch Alerts for SURF, INO, AAL, ALT, and ACB.
May 20, 2020 07:00 am ET
INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models
PLYMOUTH MEETING, Pa., May 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA vaccine, demonstrating robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2. The study was published in the peer-reviewed journal Nature Communications titled, "Immunogenicity of a DNA vaccine candidate for COVID-19" by INOVIO scientists and collaborators from The Wistar Institute, the University of Texas, Public Health England, Fudan University, and Advaccine.
May 14, 2020 07:00 am ET
INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment
PLYMOUTH MEETING, Pa., May 14, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that 85 percent (44 out of 52) of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme (GBM) who received the company's DNA medicine INO-5401, in combination with INO-9012 and PD-1 inhibitor Libtayo® (cemiplimab), were alive for at least 12 months or more (overall survival at 12 months: OS12) following treatment. These data will be featured at an oral poster presentation at the ASCO 2020 Virtual Scientific Program, May 29-31, 2020.
May 13, 2020 09:31 am ET
Thinking about buying stock in Capricor Therapeutics, Waitr, Takeda Pharmaceutical, Sorrento Therapeutics, or Inovio Pharmaceuticals?
NEW YORK, May 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, WTRH, TAK, SRNE, and INO.
May 12, 2020 08:00 am ET
INOVIO to Present at RBC Capital Markets Virtual Global Healthcare Conference
PLYMOUTH MEETING, Pa., May 12, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, along with other members of management will present in a fireside discussion at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2020 at 2:30 p.m. Eastern Time.
May 12, 2020 02:05 am ET
Barbuto & Johansson, P.A. Reminds Investors of Today’s Deadline in the Inovio Pharmaceuticals Class Action and Encourages Shareholders with Losses Exceeding $100,000 to Contact the Firm
Barbuto & Johansson, P.A. (“BARJO”) reminds investors that today is the last day to contact the Firm to learn more about the class action filed against Inovio Pharmaceuticals, Inc. (NASDAQGS: INO), and appointment of lead plaintiff. The class...
May 11, 2020 10:50 pm ET
INOVIO 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Inovio Pharma
NEW ORLEANS, May 11, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 12, 2020 to file lead plaintiff applications in a securities class action lawsuit against Inovio Pharmaceuticals (NasdaqGS: INO), if they purchased the Company's shares between February 14, 2020 and March 9, 2020, both dates inclusive (the "Class Period"). This action is pending in the United States District Court for the Eastern District of Pennsylvania.
May 11, 2020 04:05 pm ET
INOVIO Reports First Quarter 2020 Financial Results; Provides Business Update
PLYMOUTH MEETING, Pa., May 11, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases, cancer, and diseases associated with HPV, today reported financial results for the quarter ended March 31, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update, including the company's development of INO-4800, one of the leading COVID-19 vaccine candidates c
May 11, 2020 10:46 am ET
INO FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds Inovio Pharmaceuticals, Inc. Investors of Important May 11 Deadline in Securities Class Action Lawsuit – INO
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between February 14, 2020 and March 9, 2020, inclusive (the “Class Period”) of the important May 11, 2020 lead...
May 11, 2020 09:31 am ET
Thinking about buying stock in AMC Entertainment, Carnival Corp, OraSure Technologies, Inovio Pharmaceuticals, or Aytu Bioscience?
NEW YORK, May 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, CCL, OSUR, INO, and AYTU.
May 09, 2020 11:10 am ET
INOVIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Inovio Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ:INO) of the May 12, 2020 deadline to seek the role of lead plaintiff in a federal securities class...
May 08, 2020 10:50 pm ET
INOVIO 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Inovio Pharma
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 12, 2020 to file lead plaintiff applications in a securities class action lawsuit against Inovio Pharmaceuticals (NasdaqGS: INO), if they purchased the Company’s shares between February 14, 2020 and March 9, 2020, both dates inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Pennsylvania.
May 06, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS INO, NCLH, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Norwegian Cruise Line Holdings Ltd....
May 06, 2020 08:00 am ET
FINAL DEADLINE ALERT: Kaskela Law LLC Announces Deadline in Class Action Lawsuit Against Inovio Pharmaceuticals, Inc. (INO) and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi
Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) on behalf of investors who purchased shares of the Company’s stock between February 14,...
May 05, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BIDU, INO and NCLH
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Norwegian Cruise Line Holdings Ltd. (NCLH)Investors Affected: February 20, 2020 - March 12, 2020Lead Plaintiff...
May 05, 2020 04:16 pm ET
May 2020 Deadline Approaching for Inovio Pharmaceuticals (INO) Class Action
CHESTNUT HILL, Mass., May 5, 2020 /PRNewswire/ -- Sokolove Law announces an investigation into a securities class action lawsuit filed against Inovio Pharmaceuticals (NASDAQ: INO) on behalf of shareholders. INO investors that purchased 20,000 shares or more between February 14 to March 9, 2020 and are interested in learning more about the class action lawsuit should call 800-974-3478 to explore their legal rights. The May 12th deadline is approaching, time is extremely limited- shareholders are encouraged to call without delay.
May 04, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS GRPN, INO, NCLH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Norwegian Cruise Line Holdings Ltd. (NCLH) Class Period: 2/20/2020 - 3/12/2020Lead Plaintiff Motion...
May 04, 2020 09:00 am ET
Notice of Lead Plaintiff Deadline for Shareholders in the Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) common stock between February 14, 2020 and March 9, 2020 (the “Class Period”). The case is captioned McDermid v. Inovio
May 01, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BIDU, INO, NCLH, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Norwegian Cruise Line Holdings Ltd. (NCLH)Class...
May 01, 2020 11:03 am ET
BARBUTO & JOHANSSON LITIGATION UPDATE: The Law Firm Reminds Investors of Upcoming Class Action Deadlines
Barbuto & Johansson, P.A. (“BARJO”) informs investors of the pending class action lawsuits against Norwegian Cruise Lines (NYSE: NCLH) and Inovio Pharmaceuticals, Inc. (NASDAQGS: INO), as well as the upcoming deadlines to petition the court for...
Apr 30, 2020 08:00 am ET
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI
PLYMOUTH MEETING, Pa., April 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support large-scale manufacturing of INOVIO's investigational DNA vaccine INO-4800, which currently is in Phase 1 clinical testing in the U.S. for COVID-19 and could potentially advance to Phase 2/3 efficacy trials this summer. The agreement is being partly funded by an initial grant of $1.3 million from the Coalition for Epidemic Preparedness Innova
Apr 29, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS INO, NCLH, TLRY, WWE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Tilray, Inc. (TLRY)Class Period: 1/15/2019 - 3/2/2020Lead Plaintiff Motion Deadline: May 5,...
Apr 28, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BIDU, INO and NCLH
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Norwegian Cruise Line Holdings Ltd. (NCLH)Investors Affected: February 20, 2020 - March 12, 2020Lead Plaintiff...
Apr 28, 2020 04:30 pm ET
INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, April 28, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) and GeneOne Life Science (KSE:011000) today announced interim data through week 16 from a Phase 1/2a trial of DNA vaccine INO-4700 (also called GLS-5300) for MERS coronavirus (MERS-CoV). Vaccine recipients demonstrated strong antibody and T cell immune responses after 2 or 3 doses with 0.6 mg of INO-4700, a DNA vaccine that targets the MERS-CoV Spike (S) glycoprotein, delivered with intradermal CELLECTRA® device. The vaccination regimen was well-tolerated with no vaccine-associated severe adverse
Apr 28, 2020 09:31 am ET
Thinking about buying stock in Quotient, Eldorado Resorts, Carnival Corp, Inovio Pharmaceuticals, or American Eagle Outfitters?
NEW YORK, April 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QTNT, ERI, CCL, INO, and AEO.
Apr 28, 2020 08:00 am ET
INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June
PLYMOUTH MEETING, Pa., April 28, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced that its Phase 1 U.S. clinical trial for COVID-19 DNA vaccine INO-4800 is fully enrolled with all 40 healthy volunteers receiving their first dose, with interim immune responses and safety results expected in late June. The 40 healthy volunteers now enrolled at sites at the University of Pennsylvania in Philadelphia, PA, and a clinic in Kansas City, MO, will receive two doses of INO-4800 four weeks apart. The Phase 1 study is designed to assess the safety profile and immunogenicity of INO-4800 in suppor
Apr 27, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BIDU, INO, NCLH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Inovio Pharmaceuticals (INO)Class Period:...
Apr 27, 2020 03:48 pm ET
Shareholder Alert: Robbins LLP Reminds Investors the Lead Plaintiff Deadline is Approaching for Inovio Pharmaceuticals, Inc. (INO) Class Action
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 14, 2020 and March 9, 2020. Inovio is a late-stage biotechnology
Apr 27, 2020 12:18 pm ET
Citron Research Further Criticizes Inovio Pharmaceuticals, Inc.; Investors Who Lost Money Should Contact Block & Leviton LLP Who Filed First Shareholder Lawsuit
Today, research analyst Citron Research published a report calling Inovio (NASDAQ: INO) “The COVID-19 Version of Theranos,” in which Citron slashed its target price for Inovio common stock by 93%. Block & Leviton LLP (www.blockesq.com), a...
Apr 27, 2020 08:00 am ET
INOVIO to Report First Quarter 2020 Financial Results on May 11, 2020
PLYMOUTH MEETING, Pa., April 27, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) announced today that first quarter 2020 financial results will be released after the market close on May 11, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update, including the company's ongoing vaccine developments for COVID-19.
Apr 24, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ALGN, INO, TLRY, WWE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Align Technology, Inc. (ALGN)Class Period: 4/24/2019 - 7/24/2019Lead Plaintiff Motion Deadline: May 1,...
Apr 24, 2020 03:47 pm ET
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Inovio Pharmaceuticals, Inc. Investors
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Inovio Pharmaceuticals, Inc. (NASDAQ: INO) (“Inovio”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of...
Apr 24, 2020 09:31 am ET
Thinking about buying stock in Advanced Micro Devices, Carnival Corp, eBay, Inovio Pharmaceuticals, or Tilray?
NEW YORK, April 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, CCL, EBAY, INO, and TLRY.
Apr 22, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Aaron’s, Inc. (AAN) Class Period: 3/2/2018 -...
Apr 22, 2020 10:50 am ET
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of INO, XP and GOSS
NEW YORK, NY / ACCESSWIRE / April 22, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Apr 21, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AAN, BDX, FLR and INO
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Becton, Dickinson and Company (BDX) Investors Affected: November 5, 2019 - February 5, 2020Lead Plaintiff Motion...
Apr 20, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ALGN, INO, TLRY, WWE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Align Technology, Inc. (ALGN) Class Period: 4/24/2019 - 7/24/2019Lead Plaintiff Motion Deadline: May 1,...
Apr 17, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Aaron’s, Inc. (AAN) Class Period: 3/2/2018 -...
Apr 17, 2020 12:02 pm ET
Zhang Investor Law Announces Securities Class Action Lawsuit Against Inovio Pharmaceuticals, Inc. – INO
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between February 14, 2020 and March 9, 2020, inclusive (the “Class Period”). If you wish to serve as lead...
Apr 16, 2020 06:00 am ET
IVI, INOVIO, and KNIH to Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, April 16, 2020 /PRNewswire/ -- The International Vaccine Institute (IVI) announced today that the Coalition for Epidemic Preparedness Innovations (CEPI) has granted $6.9 million funding to INOVIO (NASDAQ:INO) to work with IVI and the Korea National Institute of Health (KNIH) for a Phase 1/2 clinical trial of INOVIO's COVID-19 vaccine candidate (INO-4800) in South Korea. IVI will conduct the trial in parallel to INOVIO's Phase 1 INO-4800 study currently underway in the US since April 6, 2020 with 40 healthy adults receiving the vaccine candidate a
Apr 15, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ALGN, INO, TLRY, WWE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Align Technology, Inc. (ALGN) Class Period: 4/24/2019 - 7/24/2019Lead Plaintiff Motion Deadline: May 1,...
Apr 15, 2020 04:01 pm ET
INOVIO to Host its Annual Meeting of Stockholders in Virtual Format and at a New Time
PLYMOUTH MEETING, Pa., April 15, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting of Stockholders (the 2020 Annual Meeting) will now be held by means of a virtual format only and will be held at a new time at 2:00 pm Eastern Time. The date of the meeting (May 14, 2020), as disclosed in INOVIO's proxy statement for the meeting, has not changed.
Apr 15, 2020 09:00 am ET
Notice of Lead Plaintiff Deadline for Shareholders in the Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) common stock between February 14, 2020 and March 9, 2020 (the “Class Period”). The case is captioned McDermid v. Inovio
Apr 14, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AAN, BDX, FLR and INO
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Becton, Dickinson and Company (BDX) Investors Affected: November 5, 2019 - February 5, 2020Lead Plaintiff Motion...
Apr 13, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Aaron’s, Inc. (AAN)Class Period: 3/2/2018 -...
Apr 12, 2020 12:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
NEW YORK, April 12, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Apr 12, 2020 12:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
NEW YORK, April 12, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Apr 10, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ALGN, INO, TLRY, WWE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Align Technology, Inc. (ALGN)Class Period: 4/24/2019 - 7/24/2019Lead Plaintiff Motion Deadline: May 1,...
Apr 10, 2020 10:40 am ET
Inovio Investor Alert: Class Action Lawsuit Lead Plaintiff Deadline
Boston, Massachusetts--(Newsfile Corp. - April 10, 2020) - Investors interested to be a lead plaintiff in a shareholder lawsuit filed against Inovio Pharmaceuticals (NASDAQ: INO) have until May 12, 2020 to retain an attorney and file the necessary motion papers. There is no minimum number of shares required to be a class member. Shareholders who purchased at least $150,000 shares of INO stock between February 14, 2020 and March 9, 2020 and are interested in serving as a lead plaintiff are encouraged to contact the Thornton Law Firm LLP by visiting https://www.tenlaw.com/cases/INO. Shareholders may also contact the Thornton Law Firm at [email protected], or call 617-531-3917.
Apr 10, 2020 12:03 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 09, 2020 06:07 pm ET
KESSLER TOPAZ MELTZER & CHECK, LLP - IMPORTANT DEADLINE REMINDER FOR INOVIO PHARMACEUTICALS, INC. INVESTORS
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Inovio Pharmaceuticals, Inc. (NASDAQ: INO) (“Inovio”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of...
Apr 08, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Aaron’s, Inc. (AAN) Class Period: 3/2/2018 -...
Apr 07, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AAN, BDX, FLR and INO
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Becton, Dickinson and Company (BDX) Investors Affected: November 5, 2019 - February 5, 2020Lead Plaintiff Motion...
Apr 06, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ALGN, INO, TLRY, WWE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Align Technology, Inc. (ALGN)Class Period: 4/24/2019 - 7/24/2019Lead Plaintiff Motion Deadline: May 1,...
Apr 06, 2020 08:24 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Inovio Pharmaceuticals (INO) Investors with Significant Losses to Contact its Attorneys: Important Application Deadline Approaching
Hagens Berman urges investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) who have suffered significant losses to submit their losses now. A securities fraud class action has been filed against the Company and certain investors may have valuable...
Apr 06, 2020 08:30 am ET
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
PLYMOUTH MEETING, Pa., April 6, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for INO-4800, its DNA vaccine candidate designed to prevent COVID-19 infection, paving the way for Phase 1 clinical testing of INO-4800 in healthy volunteers beginning this week. The first dosing is planned for today.
Apr 04, 2020 10:18 am ET
Kessler Topaz Meltzer & Check, LLP Reminds Inovio Pharmaceuticals, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Inovio Pharmaceuticals, Inc. (NASDAQ: INO) (“Inovio”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of...
Apr 03, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Aaron’s, Inc. (AAN) Class Period: 3/2/2018 -...
Apr 02, 2020 02:16 pm ET
Shareholder Alert: Robbins LLP Reminds Investors Inovio Pharmaceuticals, Inc. (INO) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 14, 2020 and March 9, 2020. Inovio is a late-stage biotechnology Co
Apr 01, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ALGN, INO, TLRY, WWE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Align Technology, Inc. (ALGN) Class Period: 4/24/2019 - 7/24/2019Lead Plaintiff Motion Deadline: May 1,...
Apr 01, 2020 07:21 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 01, 2020 10:30 am ET
SHAREHOLDER ALERT: Inovio Pharmaceuticals, Inc. Officers and Directors Under Investigation for Allegedly Misleading Statements Concerning COVID-19 Vaccine
SAN FRANCISCO, April 1, 2020 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential shareholder derivative claims on behalf of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) ("Inovio" or the "Company"), related to allegedly misleading statements about the company's development of a purported vaccine for the novel coronavirus.
Mar 31, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AAN, BDX, FLR and INO
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Becton, Dickinson and Company (BDX)Investors Affected: November 5, 2019 - February 5, 2020Lead Plaintiff Motion...
Mar 30, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Aaron’s, Inc. (AAN)Class Period: 3/2/2018 -...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.